Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

Group announced that the U.S. Food and Drug Administration, FDA, has accepted the Biologics License Application, BLA, for RP1 ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare ...

Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.

For patients with advanced gastric and gastroesophageal junction cancer, nivolumab improves overall and progression-free survival.